Synlogic Inc Clinical Program Update Call Transcript
Good morning. Welcome to Synlogic's Clinical Program Update Call. (Operator Instructions) Please be advised that this call is being recorded. I would now like to turn the call over to Daniel Rosan, Head of Finance and Investor Relations. Please proceed.
Thank you, operator. Good morning, everybody, and thank you for joining us on today's conference call. This morning, we issued a press release, which outlines progress in our phenylketonuria program and additional business updates. This release is available on the Investors section of our website at synlogictx.com.
Joining me this morning are Dr. Aoife Brennan, President and Chief Executive Officer; and Dr. David Hava, Chief Scientific Officer. Other members of the Synlogic management team will be available during the Q&A.
Before we begin, I'd like to remind everyone that comments today may include forward-looking statements made under the Private Securities Litigation Reform Act of 1995. These forward-looking statements
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |